Sign inCreate account

Report workspace tools

NCT00870480COMPLETEDanonymous

Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions.

Sponsor

Source record

Actavis Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Finasteride

Indication / condition

AI-normalized

Healthy

Intervention

Source record

Finasteride 5 mg Tablet, single dose, Proscar® 5 mg Tablet, single dose

Source & freshness

Source record

NCT ID

NCT00870480

Original source

ClinicalTrials.gov

Source last updated

Aug 16, 2010

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00870480

Title

Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions.

Sponsor

Actavis Inc.

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy

Condition normalized

Healthy

Modality raw

Healthy

Modality normalized

small molecule

Target raw

Finasteride

Target normalized

Finasteride

Interventions

Finasteride 5 mg Tablet, single dose, Proscar® 5 mg Tablet, single dose

Public preview

Source record

This clinical trial, sponsored by Actavis Inc., aimed to evaluate the bioequivalence of Finasteride 5 mg tablets compared to Proscar under fasting conditions in healthy male subjects. The study was completed in November 2004 with 26 participants enrolled in a randomized, 2-way crossover design.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00870480

Status

COMPLETED

Phase

PHASE1

Sponsor

Actavis Inc.

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Actavis Inc., aimed to evaluate the bioequivalence of Finasteride 5 mg tablets compared to Proscar under fasting conditions in healthy male subjects. The study was completed in November 2004 with 26 participants enrolled in a randomized, 2-way crossover design.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 16, 2010
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00870480

Indication

Healthy

Modality

small molecule

Target

Finasteride

Intervention

Finasteride 5 mg Tablet, single dose, Proscar® 5 mg Tablet, single dose

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.